Pleural Effusion

Meet the patient

A 68-year-old former smoker arrives with two weeks of progressive breathlessness and a sharp, pleuritic pain over the right base that has eased as he became more breathless. He is tachypnoeic; the right base is stony dull with absent breath sounds and reduced vocal resonance, and the trachea is pushed slightly to the left.^[2]

The two questions that decide his next 24 hours are the two that decide every pleural effusion: is the lung pushed away by fluid, or pulled in by collapse? (the trachea answers at the bedside — pushed away means effusion), and once you have confirmed fluid, is it a transudate or an exudate? (the tap answers that). Hold those two questions and everything below slots into place.^[1]

Light's criteria — the one fork that runs everything

A pleural effusion is not a diagnosis; it is a sign of an underlying disease. The single most powerful diagnostic step, introduced by Richard Light in 1972 and unchanged in half a century, is to classify the fluid as a transudate or an exudate. That one distinction collapses a differential of dozens of causes into two manageable lists, and it dictates which further fluid tests are worth sending.^[1][2]

Light's criteria compare simultaneous serum protein and LDH against the pleural fluid. The effusion is an exudate if any ONE of the three holds:^[1][13]

• Pleural fluid protein divided by serum protein over 0.5
• Pleural fluid LDH divided by serum LDH over 0.6
• Pleural fluid LDH over 200 U/L^[13]

The criteria are highly sensitive but less specific. In the prospective series that tested them head-to-head against the albumin gradient, Light's criteria correctly identified every exudate, but five patients with congestive heart failure were misclassified as exudates — four of them after diuretic therapy — and about a quarter of heart-failure effusions fall into the exudative range biochemically.^[13][14] The two rescue tests for that trap are pleural fluid NT-proBNP — at a cut-off of 4000 ng/L it identified cardiac effusions with about 92 per cent accuracy and correctly reclassified every patient Light's criteria had mislabelled — and, where natriuretic peptide assays are unavailable, the serum-to-pleural-fluid albumin gradient, where a gradient over 1.2 g/dL supports a transudate.^[15][13][14]

Enlarge

The four mechanisms — and which fork they land on

A transudate forms when systemic Starling forces are disturbed across a normal pleura; an exudate forms when the pleura itself is diseased. Recognising the mechanism predicts the transudate-exudate split before the tap.^[1][10]

Enlarge

1. Increased hydrostatic pressure (transudate). Pulmonary venous pressure rises in left heart failure, mitral stenosis, fluid overload and constrictive pericarditis; pleural effusion results from increased interstitial fluid in the lung due to elevated pulmonary capillary pressure.^[14]
2. Decreased oncotic pressure (transudate). Hypoalbuminaemia from cirrhosis, nephrotic syndrome or severe malnutrition lowers plasma oncotic pressure. Hepatic hydrothorax is the paradigm — ascites tracks through small diaphragmatic defects into the negative-pressure pleural space, typically producing a unilateral right-sided effusion.^[12]
3. Increased capillary permeability (exudate). Inflammation from pneumonia, autoimmune disease, pulmonary embolism with infarction, pancreatitis or drugs opens intercellular junctions and lets protein-rich fluid leak in — the fibropurulent stage of a parapneumonic effusion is the classic example.^[16]
4. Impaired lymphatic drainage (exudate). Obstruction by tumour or nodes raises back-pressure and traps protein, so even normal-constituency fluid accumulates as an exudate.^[1]

The benign (non-malignant) effusions outnumber the malignant ones by at least three to one, and in recent United States epidemiological data 75 per cent of resource allocation for pleural effusion management is spent on non-malignant effusions (excluding empyema) — yet they do not follow a benign course, with mortality that matches and sometimes exceeds malignant effusions.^[10]

The epidemiology is the epidemiology of its causes, and the side matters at the bedside. Heart-failure effusions are typically bilateral, but when unilateral they are more commonly right-sided — so a unilateral right-sided effusion in heart failure is a common explanation, not a reason to chase an alternative cause first.^[14]

In tuberculosis-endemic regions pleural tuberculosis remains one of the most frequent causes of a pleural exudate, particularly in tuberculosis-endemic areas and in people living with HIV.^[21] The incidence of pleural infection in adults has been continuously increasing over the past two decades, particularly in older adults with comorbidities, and management requires a prolonged hospitalisation — 14 days on average in contemporary series.^[17]

At the bedside — stony dull and shifted away

The classical symptom triad is progressive exertional dyspnoea, pleuritic chest pain and a dry cough. Dyspnoea is the commonest and most reliable symptom; pleuritic pain arises from the parietal pleura (the visceral pleura is insensate) and therefore points to an exudative cause — pneumonia, pulmonary embolism, autoimmune — rather than a transudate. The pain often eases as fluid accumulates and separates the inflamed pleural surfaces.^[2]

Examination yields one of the most distinctive bedside findings in medicine. The affected hemithorax is expanded, moves less on respiration, and is dull to percussion. The percussion note is "stony dull" — a dense, thud-like quality distinct from the woody dullness of consolidation, because fluid transmits vibration poorly. Breath sounds and vocal resonance are reduced or absent over the fluid, and a pleural rub may sit at the upper margin where the two pleural surfaces still rub. The trachea and apex beat are deviated away in a massive effusion.^[2]

Everyone forgets the trachea. Effusion pushes the mediastinum away; collapse pulls it toward. That single sign separates the two at the bedside before any imaging, and it is the discriminator examiners listen for.^[4]

The differential of dullness with reduced breath sounds

The bedside finding of dullness with reduced breath sounds has a focused differential, and the examiner expects you to distinguish each by the features that separate them.^[2][4]

^[2]

The discriminator line: trachea away equals effusion; trachea toward equals collapse; bronchial breathing with increased resonance equals consolidation.^[2]

Diagnostic thoracentesis — what to send, what to skip

The investigation proceeds in two phases: confirm the effusion (imaging), then identify the cause (pleural fluid analysis). The cornerstone is the diagnostic thoracentesis with pleural fluid interpreted through Light's criteria.^[1][4]

Tap every unexplained unilateral effusion, every bilateral effusion with discordant appearances, and any effusion that does not resolve with heart failure treatment. Perform it under ultrasound guidance — ultrasound confirms fluid, and it is one of the most useful tests for detecting the loculated or septated collections that mark a complicated parapneumonic effusion.^[16]

The first and decisive step is to apply Light's criteria to the fluid, comparing simultaneous serum protein and LDH. Once classified as a transudate, no further fluid tests are usually needed — the workup shifts to the systemic cause. Once it is an exudate, a panel of additional tests refines the diagnosis:^[1][13]

• Glucose — under 60 mg/dL (about 3.3 mmol/L), together with a low pH and a high LDH, defines the fibropurulent stage of a parapneumonic collection.^[16]
• pH — under 7.20 marks a complicated parapneumonic effusion; meta-analysis of the primary studies found pH the most accurate single discriminator (area under the ROC curve 0.92, versus 0.84 for glucose and 0.82 for LDH), with decision thresholds falling between 7.21 and 7.29 depending on cost-prevalence considerations.^[19]
• Cell count — neutrophils point to bacterial infection or its complications; lymphocytes point to tuberculosis or malignancy. Tuberculous effusions are characteristically lymphocyte-rich, straw-coloured and free-flowing.^[21]
• Gram stain and culture, AFB — bacterial and mycobacterial; tuberculous pleural effusions have a characteristically low yield on mycobacterial culture, so a negative culture never excludes tuberculosis.^[21]
• Cytology — pooled diagnostic sensitivity for a malignant effusion is 58.2 per cent (range 20.5 to 86.0 across studies); it is highest for lung adenocarcinoma (83.6 per cent) and ovarian cancer (85.2 per cent) and lowest for lung squamous carcinoma (24.2 per cent) and mesothelioma (28.9 per cent).^[20]
• ADA — at a threshold around 40 U/L (studies used 40 plus or minus 4 IU/L) the summary sensitivity for tuberculous pleural effusion is 0.93 and the specificity 0.90.^[22]
• Triglycerides — over 110 mg/dL (about 1.24 mmol/L), or chylomicrons on lipid electrophoresis, defines a chylous effusion.^[23]

The macroscopic appearance gives the first clue: serous and straw-coloured (transudate or early exudate), bloody (malignancy, trauma, PE, iatrogenic), turbid or purulent (empyema), milky white (chylothorax or pseudochylothorax), food particles (oesophageal rupture).^[2][23]

^{[13] [16] [20] [22] [23] [15]}

The drainage thresholds — pH, glucose, pus

The decision to drain a parapneumonic effusion rests on the fluid biochemistry: a pH under 7.20, a glucose under 60 mg/dL, or a high LDH mark the fibropurulent stage, in which antibiotic therapy alone is not enough for resolution and an invasive procedure — pleural drainage or surgery — is required; frankly purulent fluid is empyema by definition.^[16] Meta-analysis of the primary studies confirms the hierarchy: pleural fluid pH had the highest diagnostic accuracy (AUC 0.92), retaining the top position even after frankly purulent effusions were excluded (AUC 0.89), with decision thresholds between 7.21 and 7.29.^[19]

Parapneumonic effusions stratify into three stages that map directly onto management:^[16]

^{[16] [6]}

Resuscitation — the four time-critical effusions

Enlarge

Most effusions are managed electively, but a small number present as time-critical emergencies in which the resuscitation reflex precedes the diagnostic workup. The dangerous scenarios are tension pleural effusion, massive haemothorax, empyema with septic shock, and severe hypoxaemia from a large malignant effusion.^[2][5]

Tension pleural effusion is rare but lethal — a large effusion under pressure that shifts the mediastinum away, compresses the great veins, and produces hypotension, tachycardia, marked dyspnoea and hypoxaemia. Immediate management is emergency needle aspiration followed promptly by an intercostal chest drain.^[2]

Massive haemothorax is a surgical emergency. Most cases of haemothorax follow blunt or penetrating chest trauma, and the criteria for surgical intervention in the initial haemothorax are well defined; what remains controversial is the best approach to a retained haemothorax after the initial drain. Drain the chest, resuscitate with intravenous crystalloid and blood, correct coagulopathy, and involve thoracic surgery early.^[27]

Empyema with septic shock requires simultaneous resuscitation and source control: intravenous fluids, vasopressors for refractory hypotension, antimicrobial therapy with mandatory anaerobic coverage, and chest-tube drainage — the two key components of pleural infection management — escalating to surgery or intrapleural fibrinolytics when sepsis persists despite standard measures.^[17][6]

The one procedural limit everyone must know — and its evidence: re-expansion pulmonary oedema is the feared complication of therapeutic thoracentesis, but in a prospective series of 185 large-volume thoracenteses (a litre or more removed) clinical oedema occurred in only one patient (0.5 per cent) and radiographic-only oedema in four (2.2 per cent), with no association with the volume removed, the pleural pressure or the pleural elastance. The evidence therefore supports draining a large effusion to completion, stopping for chest discomfort or an end-expiratory pleural pressure below minus 20 cm of water, rather than stopping at an arbitrary volume.^[25]

Parapneumonic effusion and empyema — MIST-2 changed the rule

Antibiotics for pleural infection must cover anaerobes — anaerobic coverage is mandatory, because anaerobes are a major cause of pleural infection — and the expected spectrum differs between community-acquired and healthcare-associated infection, so the regimen must be chosen accordingly.^[17] Conventional teaching is a minimum of four weeks of treatment, though that figure rests on expert opinion; a randomised trial comparing a short course (14 to 21 days) with a long course (28 to 42 days) in medically stabilised patients found no significant difference in treatment failure (16.7 versus 12.5 per cent).^[18]

Intrapleural tPA plus DNase was established by the MIST-2 trial (Rahman 2011): in a blinded two-by-two factorial trial, 210 patients with pleural infection received double placebo, tPA plus DNase, tPA alone, or DNase alone, each for three days. The combination significantly increased pleural drainage (mean change in pleural opacity minus 29.5 versus minus 17.2 per cent with placebo), reduced surgical referral at three months (4 versus 16 per cent) and shortened the hospital stay by a mean of 6.7 days. The trap examiners love: tPA alone and DNase alone were no better than placebo, and DNase alone actually increased surgical referral (39 versus 16 per cent).^[6] Intrapleural fibrinolytic-enzymatic therapy is the option when a chest tube fails to clear a loculated collection or the patient is not suitable for surgery.^[16][17]

Surgical decortication is indicated for failed medical therapy — persistent sepsis despite standard measures — with intrapleural fibrinolytic therapy recommended for poor surgical candidates.^[17] The RAPID score (Rahman 2014) — Renal (urea), Age, Purulence, Infection source, Dietary (albumin) — stratifies three-month mortality into low (0 to 2), medium (3 to 4) and high (5 to 7) risk; in the MIST-2 validation cohort a high-risk score carried an odds ratio of 14.1 for death at three months.^[9]

Malignant effusion — IPC or talc, take your pick

A malignant effusion is a symptom-control problem layered on an oncology problem. The fluid is usually an exudate, and pleural fluid cytology makes the diagnosis in 58.2 per cent of cases overall — highest in lung adenocarcinoma (83.6 per cent) and ovarian cancer (85.2 per cent), lowest in mesothelioma (28.9 per cent), which usually needs a pleural biopsy instead.^[20][11]

The TIME2 trial (Davies 2012) compared an indwelling pleural catheter with chest tube and talc slurry pleurodesis: dyspnoea improved in both groups with no significant difference over the first 42 days (mean visual-analogue dyspnoea score 24.7 versus 24.4 mm), the IPC group was significantly better at six months (difference minus 14.0 mm), and the initial hospitalisation was dramatically shorter (median 0 versus 4 days) — at the cost of more adverse events (21 of 52 versus 7 of 54) and fewer further pleural procedures (3 versus 12).^[7] The IPC-Plus trial (Bhatnagar 2018) then showed that talc slurry instilled through an existing IPC produced successful pleurodesis at 35 days in 43 per cent versus 23 per cent with placebo (hazard ratio 2.20), without excess harm — combining the convenience of an IPC with the pleurodesis effect.^[8]

Current practice therefore presents IPC and talc pleurodesis as equivalent first-line options for dyspnoea relief, with the choice guided by lung re-expansion (a trapped lung precludes pleurodesis) and expected prognosis.^[3][7] Mesothelioma-related effusions deserve pleural biopsy — image-guided or thoracoscopic — for diagnosis, with BAP1 or MTAP loss and CDKN2A homozygous deletion as the basic molecular markers, and the effusion managed with tunnelled pleural catheters, alone or combined with aerosolised talc during a diagnostic thoracoscopy.^[11]

The specific-cause one-liners that earn marks

Tuberculous pleuritis is treated with antituberculous regimens identical to those used for pulmonary tuberculosis.^[21] The effusion is typically an exudate that is lymphocyte-rich, straw-coloured and free-flowing with a high ADA and a characteristically low yield on mycobacterial culture — up to 80 per cent of patients also have parenchymal involvement on chest imaging. Where tuberculosis prevalence is high, a lymphocyte-predominant exudate with a high ADA carries a positive predictive value of 98 per cent; in low-prevalence areas the absence of both makes tuberculosis very unlikely and pleural biopsy should be performed to confirm the diagnosis, and to obtain culture and susceptibility testing where drug resistance is prevalent. Initial pleural drainage may have a role in symptom relief and in hastening resolution.^[21]

Hepatic hydrothorax develops in 5 to 10 per cent of patients with liver cirrhosis, typically as a unilateral, right-sided pleural effusion with concomitant ascites, from small diaphragmatic defects (pleuroperitoneal connections) that let ascitic fluid migrate directly into the pleural cavity.^[12] Never put a chest tube: in a 10-year series of 17 patients drained this way, 16 suffered at least one complication — acute kidney injury in 11, pneumothorax in 7, empyema in 5 — and six were dead within three months, whereas six of seven who received TIPS survived.^[26] Medical management is sodium restriction and diuretic therapy, with thoracentesis for symptomatic relief; refractory cases go for TIPS, as definitive treatment or a bridge to liver transplantation — the only curative option.^[12]

Chylothorax is a lymphocyte-predominant effusion caused by thoracic duct leakage into the pleural space, defined by a pleural fluid triglyceride concentration over 110 mg/dL (about 1.24 mmol/L) or the presence of chylomicrons; chylous effusions from a duct leak alone are typically protein-discordant exudates with a low LDH, and fluid that falls outside that pattern should prompt a search for a coexisting cause, because that changes management.^[23]

Rheumatoid pleuritis has a distinctive fluid signature — high LDH with low pH and low glucose; it usually occurs in middle-aged men, and a contemporary series found most patients were over 60, with milder fluid abnormalities (lower LDH, higher pH) in older patients and a distinctly higher mortality than previously reported.^[28]

A consultant confession: distinguish chylothorax from pseudochylothorax. A true chylothorax is from a thoracic duct leak and has triglycerides over 110 mg/dL; a pseudochylothorax (cholesterol pleurisy, chyliform effusion) is a cholesterol-rich effusion of chronic inflammatory disease — 88.5 per cent of published cases were tuberculosis or rheumatoid arthritis — with a milky exudate, lymphocyte predominance in 61.1 per cent, cholesterol crystals (89.7 per cent sensitive) and a cholesterol-to-triglyceride ratio over 1 (97.4 per cent sensitive), and it is not managed with a low-fat diet.^[24][23]

Chest tubes — the smallest effective drain

The modern principle is the smallest effective drain. A small-bore Seldinger drain, inserted under ultrasound guidance, is preferred for most free-flowing effusions, complicated parapneumonic effusion and many empyemas, because it is more comfortable and equally effective when correctly placed; a larger-bore drain is reserved for frank pus, haemothorax and large-volume air leaks. The BTS recommends ultrasound guidance for every pleural drain.^[4]

Drain care matters: assess output and swing regularly, keep the tube patent, never clamp a chest tube in a ventilated patient or a pneumothorax, and remove it once the effusion has resolved and the lung re-expanded.^[4]

When it goes wrong — the preventable list

• Missing empyema — a parapneumonic collection with pH under 7.20 or glucose under 60 mg/dL is complicated and needs drainage, because antibiotic therapy alone is not enough for its resolution.^[16]
• Putting a chest tube in hepatic hydrothorax — 16 of 17 patients in one series suffered complications including acute kidney injury, pneumothorax and empyema; use sodium restriction, diuretics, therapeutic thoracentesis, and TIPS or transplantation for refractory disease.^[26]
• Stopping a therapeutic tap too early out of fear of re-expansion oedema — clinical oedema complicated only 0.5 per cent of 185 large-volume thoracenteses; drain to completion but stop for chest discomfort.^[25]
• Pleurodesis in a trapped lung — pleurodesis cannot succeed if the lung does not re-expand; choose an indwelling pleural catheter instead.^[3]
• Mislabelling a diuretic-treated cardiac effusion as an exudate — rescue with pleural fluid NT-proBNP (4000 ng/L cut-off, 92 per cent accuracy) or the serum-to-pleural albumin gradient over 1.2 g/dL.^[15][13]
• Missing a tuberculous effusion in a high-burden setting — a lymphocytic exudate with a high ADA carries a positive predictive value of 98 per cent for tuberculosis.^[21]
• Giving DNase alone in empyema — MIST-2 showed it increased surgical referral to 39 per cent; only tPA plus DNase together works.^[6]

Prognosis, disposition, and the score that sets both

The prognosis of a pleural effusion is the prognosis of its cause. Transudative effusions generally improve with treatment of the underlying disease. Pleural infection carries considerable morbidity and remains life-threatening — more than 30 per cent of patients with pleural infection either die or require surgery — and the RAPID score quantifies that risk at three months from age, urea, albumin, hospital-acquired infection and non-purulence.^[6][9]

Malignant pleural effusion is a marker of advanced disease with a limited median survival measured in months, and the choice between pleurodesis and an indwelling catheter is guided by lung re-expansion, performance status and expected prognosis.^[3][7]

Disposition follows the cause and the patient's physiology. Outpatient management suits a stable transudate with a treatable cause and a small exudate under investigation. Inpatient management is required for drainage, sepsis, massive or tension effusion, haemothorax, diagnostic uncertainty, and significant comorbidity — pleural infection alone averages 14 days of hospitalisation.^[17] Every patient needs a follow-up chest X-ray to document resolution, because a non-resolving effusion mandates reinvestigation.^[4]

Special populations

In the elderly, heart failure, pneumonia and malignancy all rise with age, reserve is lower, and the incidence of pleural infection is increasing fastest in older adults with comorbidities — lower the threshold for inpatient management.^[17] In pregnancy, a large or symptomatic effusion always needs a workup rather than reassurance, with heart failure, pulmonary embolism and infection the leading considerations.^[14]

The immunocompromised are at risk for a broader spectrum of infection — bacterial, mycobacterial (including non-tuberculous), fungal and parasitic — and a wider differential for an exudative effusion, including tuberculosis at any CD4 count.^[21] The anticoagulated patient needs the INR checked and corrected before thoracentesis, and a bloody effusion in an anticoagulated patient still needs investigation for malignancy and pulmonary embolism.^[4]

The evidence — BTS, MIST-2, TIME2

The British Thoracic Society Pleural Disease Guideline 2010 — Roberts on the malignant effusion, Hooper on investigation of a unilateral effusion, Davies on pleural infection — set the framework for contemporary practice.^[3][4][5] Contemporary syntheses restate its algorithm: chest imaging with ultrasound first, thoracentesis interpreted through Light's criteria, then cause-directed fluid tests; drainage for the complicated parapneumonic collection (pH under 7.20, glucose under 60 mg/dL); antimicrobial therapy with anaerobic cover plus chest-tube drainage for pleural infection, escalating to surgery or intrapleural fibrinolytics on failure.^[16][17]

The 2011 MIST-2 trial transformed loculated empyema: intrapleural tPA plus DNase, each given daily for three days, improved drainage, cut surgical referral and shortened hospital stay — neither agent alone works, and DNase alone is harmful.^[6] The 2014 RAPID score then provided a validated three-month mortality risk score for pleural infection.^[9]

For malignant effusion, TIME2 (2012) showed an indwelling pleural catheter gave dyspnoea relief equivalent to talc pleurodesis at 42 days (24.7 versus 24.4 mm on a visual-analogue scale) with better dyspnoea at six months, and IPC-Plus (2018) showed talc instilled through an existing IPC increased pleurodesis rates (43 versus 23 per cent at 35 days). Together they established IPC and talc pleurodesis as equivalent first-line options.^[7][8][3]

The ERS 2024 statement on benign pleural effusions (Sundaralingam) synthesises the contemporary approach to a diagnostic approach to transudates, heart failure, hepatic hydrothorax, end-stage renal failure, benign asbestos-related effusion, post-surgical effusion and nonspecific pleuritis — and quantifies the burden: non-malignant effusions are at least three times more common than malignant ones and absorb 75 per cent of United States pleural-effusion resource allocation.^[10]

The mantra, and the mnemonic

^{[13] [16] [15] [12] [6]}

The mantra: transudate or exudate decides everything — Light's criteria first, tap under ultrasound, drain when pH, glucose or pus demand it.^[1]

^{[13] [15] [16] [6]}

Ward-round test — three stems, thirty seconds each

Stem 1 — the patient from the top of the topic (answer)ShowHide

The 68-year-old with two weeks of progressive dyspnoea, stony dull right base, trachea pushed left. CXR confirms a large right effusion. What is your next step, and what single result changes management most? Model: Confirm with ultrasound, then diagnostic thoracentesis under ultrasound guidance and apply Light's criteria. The single result that changes management most is the pH: a parapneumonic effusion with pH under 7.20 or glucose under 60 mg/dL is complicated and goes straight to a chest drain, because antibiotics alone will not resolve it; otherwise the transudate-exudate split and the fluid panel (cell count, Gram stain and culture, cytology, ADA, triglycerides) direct the cause hunt.^[16][19][13]

Stem 2 — the loculated empyema that will not drain (answer)ShowHide

A 55-year-old with a parapneumonic effusion has a chest drain in place but remains febrile, and the drain output is poor. CT shows a multiloculated collection. What do you add, and what must you NOT add alone? Model: This is a loculated complicated parapneumonic effusion or empyema failing simple drainage. Add intrapleural tPA plus DNase, each daily for three days (MIST-2), which increased drainage, cut surgical referral from 16 to 4 per cent and shortened hospital stay by a mean of 6.7 days. Do not give DNase alone — MIST-2 showed it increased surgical referral to 39 per cent; do not give tPA alone either, as it was no better than placebo. Continue antibiotics covering community pathogens and anaerobes, and call thoracic surgery early for persistent sepsis despite standard measures.^[6][17]

Stem 3 — the cirrhotic with a right effusion (answer)ShowHide

A 60-year-old with decompensated cirrhosis has a large right pleural effusion and tense ascites. The registrar wants to put a chest drain. What is the right call? Model: This is hepatic hydrothorax — a transudate tracking through diaphragmatic defects. Do NOT put a chest drain: a 17-patient series recorded complications in 16 — acute kidney injury in 11, pneumothorax in 7, empyema in 5 — with six deaths within three months. Treat with sodium restriction and diuretic therapy, offer therapeutic thoracentesis for symptomatic relief, and refer refractory disease for TIPS or liver transplantation, the only curative option — six of seven TIPS patients in that series survived.^[12][26]

References28ShowHide

1. [1]Light RW, Macgregor MI, Luchsinger PC, Ball WC Jr Pleural effusions: the diagnostic separation of transudates and exudates Ann Intern Med, 1972.PMID 4642731
2. [2]Feller-Kopman D, Light R Pleural Disease N Engl J Med, 2018.PMID 29466146
3. [3]Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010 Thorax, 2010.PMID 20696691
4. [4]Hooper C, Lee YCG, Maskell N Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010 Thorax, 2010.PMID 20696692
5. [5]Davies HE, Davies RJO, Davies CWH Management of pleural infection in adults: British Thoracic Society Pleural Disease Guideline 2010 Thorax, 2010.PMID 20696693
6. [6]Rahman NM, Maskell NA, West A, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection N Engl J Med, 2011.PMID 21830966
7. [7]Davies HE, Mishra EK, Kahan BC, et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial JAMA, 2012.PMID 22610520
8. [8]Bhatnagar R, Keenan EK, Morley AJ, et al. Outpatient Talc Administration by Indwelling Pleural Catheter for Malignant Effusion N Engl J Med, 2018.PMID 29617585
9. [9]Rahman NM, Kahan BC, Miller RF, Gleeson FV, Nunn AJ, Maskell NA A clinical score (RAPID) to identify those at risk for poor outcome at presentation in patients with pleural infection Chest, 2014.PMID 24264558
10. [10]Sundaralingam A, Grabczak EM, Burra P, et al. ERS statement on benign pleural effusions in adults Eur Respir J, 2024.PMID 39060018
11. [11]Porcel JM Pleural mesothelioma Med Clin (Barc), 2022.PMID 35636988
12. [12]Cilia BJ, Haridy J, Raj A, et al. Hepatic hydrothorax as a manifestation of decompensated cirrhosis: An update on current management and future directions World J Hepatol, 2025.PMID 41179726
13. [13]Roth BJ, O'Meara TF, Cragun WH The serum-effusion albumin gradient in the evaluation of pleural effusions Chest, 1990.PMID 2152757
14. [14]Porcel JM Pleural effusions from congestive heart failure Semin Respir Crit Care Med, 2010.PMID 21213200
15. [15]Kolditz M, Halank M, Schiemanck CS, Höffken G High diagnostic accuracy of NT-proBNP for cardiac origin of pleural effusions Eur Respir J, 2006.PMID 16481382
16. [16]Sorino C, Mondoni M, Lococo F, Marchetti G, Feller-Kopman D Optimizing the management of complicated pleural effusion: From intrapleural agents to surgery Respir Med, 2022.PMID 34896966
17. [17]Hassan M, Patel S, Sadaka AS, Bedawi EO, Corcoran JP, Porcel JM Recent Insights into the Management of Pleural Infection Int J Gen Med, 2021.PMID 34290522
18. [18]Hassan M, Gad-Allah M, El-Shaarawy B, El-Shazly AM, Daneshvar C, Sadaka AS The Short versus Long Antibiotic Course for Pleural Infection Management (SLIM) randomised controlled open-label trial ERJ Open Res, 2023.PMID 37057085
19. [19]Heffner JE, Brown LK, Barbieri C, DeLeo JM Pleural fluid chemical analysis in parapneumonic effusions. A meta-analysis Am J Respir Crit Care Med, 1995.PMID 7767510
20. [20]Kassirian S, Hinton SN, Cuninghame S, et al. Diagnostic sensitivity of pleural fluid cytology in malignant pleural effusions: systematic review and meta-analysis Thorax, 2023.PMID 35110369
21. [21]Shaw JA, Irusen EM, Diacon AH, Koegelenberg CF Pleural tuberculosis: A concise clinical review Clin Respir J, 2018.PMID 29660258
22. [22]Aggarwal AN, Agarwal R, Sehgal IS, Dhooria S Adenosine deaminase for diagnosis of tuberculous pleural effusion: A systematic review and meta-analysis PLoS One, 2019.PMID 30913213
23. [23]Agrawal V, Doelken P, Sahn SA Pleural fluid analysis in chylous pleural effusion Chest, 2008.PMID 18339791
24. [24]Lama A, Ferreiro L, Toubes ME, et al. Characteristics of patients with pseudochylothorax-a systematic review J Thorac Dis, 2016.PMID 27621864
25. [25]Feller-Kopman D, Berkowitz D, Boiselle P, Ernst A Large-volume thoracentesis and the risk of reexpansion pulmonary edema Ann Thorac Surg, 2007.PMID 17954079
26. [26]Orman ES, Lok AS Outcomes of patients with chest tube insertion for hepatic hydrothorax Hepatol Int, 2009.PMID 19669710
27. [27]Broderick SR Hemothorax: Etiology, diagnosis, and management Thorac Surg Clin, 2013.PMID 23206720
28. [28]Minoda SS, Sada RM, Akebo H, Tsugihashi Y, Hatta K New perspective on the clinical and laboratory characteristics of rheumatoid pleural effusion: A 29-case series Mod Rheumatol, 2025.PMID 39172636